Sociedad Española de Investigacion Ósea y Metabolismo Mineral

Revista de Osteoporosis y Metabolismo Mineral

Journal Metrics:
Citescore: 1,06 |  Academic Accelerator: 0,194 
SCImago Journal Rank : 0,12 | Google Scholar: 0,0172

Empresas Colaboradoras:

The Journal follows the Uniform Requirements standards Manuscripts Submitted to Biomedical for Journals www.icmje.org

The Journal embraces the principles and procedures dictated by the Committee on Publication Ethics (COPE) www.publicationethics.org

Author: Romm

Methods for determining vitamin D and its metabolites. Threshold value of bone manifestations

Since the time of its discovery a century ago, there have been advances into what was erroneously called “vitamin” D. It is now acknowledged that it is not a vitamin, though we continue to use that term out of custom and tacit consensus. In fact, it is an endocrine system, the vitamin D endocrine system (VDES), similar to that of other steroid hormones. Cholecalciferol or “vitamin” D3, is the threshold (physiological) nutrient of the system, synthesized from 7-dehydrocholesterol, which is produced, and found, from single-celled organisms to the skin of higher animals, including human. This route represents around 90% of the physiological contribution to the body, the rest is obtained through diet. There is another isoform, of nutritional or pharmacological contribution, ergocalciferol, “vitamin” D2 or produced by ultraviolet irradiation of ergosterol contained in fungi, yeasts, etc…[1].

Read More

Osteoporosis: definition, physiopathology and clinic

Osteoporosis poses a major health problem in modern societies, especially in women. Taking into account the aging of the Spanish population and the fact that osteoporosis an­­d fractures increase with age, with an estimate for 2029 of more than 11 million people over 65 years of age, this problem may become of the first order. Currently it is estimated that there are more than 200 million patients with osteoporosis worldwide, with increasing prevalence[1]. In Spain, the prevalence of osteoporosis in postmenopausal women over 50 years is 26.1% and in men 8.1%.
Therefore, in daily clinical practice, this condition should be diagnosed establishing the previous clinical suspicion and the patients labeled as such in order to avoid its progression and its consequences, which are fragility fractures.

Read More

The role of new imaging techniques in predicting fracture risk

In 1994, the WHO defined criteria for the diagnosis of osteoporosis using the measurement of bone mineral density (BMD). The DXA technique has established itself as the dominant technology for quantifying BMD due to:
a) strong correlation between BMD measured by DXA and bone strength in biomechanical studies,
b) Epidemiological studies that show a strong relationship between the risk of fracture and BMD,
c) For its use in clinical trials of treatments for the selection of subjects and monitoring based on its excellent precision and low radiation dose.
DXA is indicated to diagnose osteoporosis, assess fracture risk, and monitor changes in BMD over time. In recent years, there have been improvements to the initial DXA technology and it is used for other measurements beyond BMD (eg, femur geometry, vertebral fracture detection, body composition analysis).

Read More

Diagnosing osteoporosis. Bone densitometry. Fracture risk estimate

The diagnosis of osteoporosis has evolved over the years along the disease’s conceptual development. The definition of osteoporosis comes from a description offered by Albright at the outset of the 1940s for postmenopausal and corticoid-induced osteoporosis. This is considered nowadays paradigm of primary and secondary osteoporosis. Its characteristics are reduced bone mass, micro-architectural disorders, unaltered mineralization and presence of fractures[1,2]. It is a histopathological definition with the secondary clinical event. Although osteoporosis is currently the most common metabolic bone disease, rickets and osteomalacia were the main metabolic bone disease from the time of Galen and well into the 20th century[3].

Read More

Genetic studies in the diagnosing of osteoporosis and other metabolic bone diseases

The nucleus contains most of the genetic information, distributed throughout the approximately 3 billion nucleotides of human haploid DNA. The approximately 21,000 genes that encode the proteins necessary for the various organic functions are represented there, as well as an indeterminate number of genes that are transcribed into RNAs that do not encode proteins, but have regulatory functions[1].
Mitochondrial DNA is smaller, having about 16,000 nucleotides, with genes to encode 13 proteins and 24 non-coding RNAs (transfer and ribosomal)[2].
DNA changes that lead to disease can be classified according to various criteria, including:

Read More

Buscador

Generic selectors
Solo mostrar coincidencias exactas
Buscar en títulos
Buscar en cuerpo de texto
Filtrar por categorías
11
12
120181004-en
120191101-en
120191102-en
120191104-en
120201201-en
120201202-en
120201203-en
120201204-en
120211301-en
120211302-en
13
920191101-en
920211301-en
920211302-en
Brief Original
Clinical Notes
Committees
Editorial
English
Index of Authors
Index of Communications
Letter to the Director
Letter to the Editor
Oral Communications
Original Articles
Osteology images
Position Paper
Poster Communications
Presentation
Reviews
SIBOMM News
Special Article
Special Documents

Search

Generic selectors
Solo mostrar coincidencias exactas
Buscar en títulos
Buscar en cuerpo de texto
Filtrar por categorías
11
12
120181004-en
120191101-en
120191102-en
120191104-en
120201201-en
120201202-en
120201203-en
120201204-en
120211301-en
120211302-en
13
920191101-en
920211301-en
920211302-en
Brief Original
Clinical Notes
Committees
Editorial
English
Index of Authors
Index of Communications
Letter to the Director
Letter to the Editor
Oral Communications
Original Articles
Osteology images
Position Paper
Poster Communications
Presentation
Reviews
SIBOMM News
Special Article
Special Documents

Language

Search